Nabla Bio combines generative AI with large-scale, human-relevant testing to turn drug development from trial-and-error into an engineered, designable process.
The company is beginning with antibodies against the hardest, most intractable targets in medicine — designing therapeutics from first principles rather than discovering them by chance.
Founders
Surge Biswas
Co-Founder
Frances Anastassacos
Co-Founder